[Retrospective Study of Ph+/BCR-ABL+ Acute Myelogenous Leukemia]
Ya-Nan Shi1, Hong-Hao Gao1, Wen-Jun Li1
1Department of Hematology of Chinese PLA General Hospital, Beijing 100853, China.
Objective:
To investigate the clinical manifestation, features of laboratorial examination results and prognosis of patients with Ph+/BCR-ABL+ acute myelogenous leukemia(AML).
Methods:
The clinical data of 5 AML patients with Ph+/BCR-ABL+ admitted in Department of Hematology of Chinese PLA general hospital from July 2007 to May 2015 were collected and their clinical characteristics, laboatorial examination results and long-term survival were analyzed.
Results:
The median age of 5 cases was 39 years old, and 2 cases with splenomegaly. All the cases were assayed for BCR-ABL fusion gene, and 2 of them were accompanied with other molecular abnormalities. In 4 cases, Ph chromosome was not found in one case, and one was with complex karyotype. 3 cases still are live till now and are treated by traditional chemotherapy combined with TKI, and consolidated by allo-HSCT. One case treated by traditional chemotherapy survived for 6 months. And one case treated by traditional chemotherapy combined with TKI survives till to now.
Conclusion:
The survival time of Ph+/BCR-ABL+ acute myelogenous leukemia is improved by the traditional chemotherapy combined with TKI and the consolidation with allo-HSCT.
